July 31, 2026

@michaelokun

What really resonated with me during our discussions at the 36th Annual Aspen Movement Course was the application of the Gartner Hype Cycle to stem cell therapies for Parkinson's disease. The excitement surrounding several new clinical studies is real, and it should be. We are witnessing remarkable scientific advances and, for the first time, there is growing evidence that transplanted dopaminergic cells can survive, integrate, and improve motor symptoms in some people. But the Gartner curve reminds us that every transformative technology passes through predictable stages: an initial breakthrough, a Peak of Inflated Expectations, a Trough of Disillusionment as challenges become apparent, and eventually a Slope of Enlightenment leading to a Plateau of Productivity where therapies find their appropriate place in clinical care. I believe we are somewhere near that peak today. The promise is enormous, but so are the challenges, including graft survival, immune suppression, manufacturing, cost, scalability, and long-term safety. Most importantly, we must remember what these therapies are designed to do. They primarily restore dopamine to the nigrostriatal motor system, meaning they have the greatest potential to improve symptoms such as slowness, stiffness, and tremor. They are unlikely, at least in their current form, to halt the broader neurodegenerative process or fully address the gait impairment, balance problems, speech changes, swallowing difficulties, cognitive decline, or other non-motor features that often emerge as Parkinson's progresses. The future is bright, but our responsibility is to balance hope with honesty. That is how we move from hype to meaningful progress for the people we serve.